Tradestie Institutional Equity Comparison Engine

LYRA vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LYRA N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner ANRO
1Y -94.3% vs +107.4% ยท 52W Pos 1% vs 54%
Options & Structure Winner ANRO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (8th %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
1M Return +10.08%
1Y Return +107.43%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% ANRO +107.43% Spread: +187.72 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LYRA TTM Op. Margin: -25032.0% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs ANRO. Trailing 12-month operating profitability (LYRA -25032.0% vs ANRO 0.0%) and valuation multiples (LYRA N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (1) vs ANRO (6)
Institutional Metric LYRA ANRO Criterion Row Winner
Market Capitalization Scale $2.3M $1.2B Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -87.2% +0.0% Higher Growth ANRO
Operating Margin (TTM) Profitability -25032.0% 0.0% Higher Margin ANRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -404.5% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 1% ($0โ€“$38) 54% ($11โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 2.03ฮฒ ยท 94% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs ANRO Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.